Provided herein are novel biomarkers for the identification, prediction or monitoring of fibrotic pulmonary diseases (e.g. idiopathic pulmonary fibrosis (IPF)). The biomarkers provided herein may further be used for therapeutic treatment of IPF.

The disclosure is directed to methods and kits for detecting neutralizing antibodies against a coronavirus (e.g., SARS-CoV-2) in a sample, such as a plasma sample or pooled plasma composition. The methods utilize a panel of SARS-CoV-2 neutralizing antibodies as a positive control. The kit may be a rapid detection kit that measures neutralizing antibodies using the provided methods.

The present invention provides methods for the diagnosis and/or treatment of chronic kidney disease, immune complex-mediated GN, rheumatoid arthritis, and pulmonary fibrosis, and methods for identifying compounds for such therapeutic use.

The present invention provides a novel use of fibroblast growth factor 2 (FGF-2), i.e., a use of FGF-2 in preparation of medicine. The uses of the medicine are the following (a) and/or (b) and/or (c): (a) the prevention and/or treatment of lung injury; (b) the prevention and/or treatment of influenza; (c) the prevention and/or treatment of diseases caused by influenza viruses.

The present disclosure relates to a method for detecting a compound, comprising the steps of: contacting a compound with a solid analytical surface (SAS), thereby forming an SAS with an absorbed compound; contacting the SAS with the absorbed compound with a mass tag, wherein the mass tag reacts with the absorbed compound, thereby forming an SAS with a covalently mass-tagged absorbed compound; and detecting the covalently mass-tagged absorbed compound by mass spectrometry. Also disclosed is a device for collecting breath aerosol, comprising a card or an envelope, wherein the card or the envelope comprise a tab, wherein the tab is a SAS.

The present invention related to identification of therapeutic agents of the treatment, diagnosis, and prevention of pulmonary hypertension.

Methods and kits for determining, predicting, or diagnosing pulmonary artery hypertension (PAH) and for determining the efficacy of PAH therapy using biomarkers are provided.

A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.

In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma.

A tissue tester for providing an indication of the presence of disease including a first paper tissue sheet; and a filter patch treated with a color changing indicator affixed to the first paper tissue sheet. The tester may also consist of a single sheet of filter paper treated with a solution of turmeric and alcohol. The color indicator changes from yellow to brown when disease is indicated in respiratory secretions.